Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy-Reference-Cited by-同舟云学术

Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy

Published:2021-03 Issue:3 Volume:14 Page:
ISSN:1941-3149
Container-title:Circulation: Arrhythmia and Electrophysiology
language:en
Short-container-title:Circ: Arrhythmia and Electrophysiology

Author:

Al-Khatib Sana M.¹^ORCID,Mulder Hillary¹^ORCID,Wojdyla Daniel¹,Lopes Renato D.¹^ORCID,Wallentin Lars²,Alexander John H.¹^ORCID,Hijazi Ziad²^ORCID,Goto Shinya³^ORCID,Granger Christopher B.¹^ORCID

Affiliation:

1. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.M.A.-K., H.M., D.W., R.D.L., J.H.A., C.B.G.).

2. Uppsala Clinical Research Center, Uppsala University, Sweden (L.W., Z.H.).

3. Tokai University School of Medicine, Isehara, Japan (S.G.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference5 articles.

1. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study

2. Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

3. Apixaban versus Warfarin in Patients with Atrial Fibrillation

4. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial

5. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety Issues of Herb-Warfarin Interactions;Current Drug Metabolism;2024-01

2. Chronic obstructive pulmonary disease and atrial fibrillation;South Russian Journal of Therapeutic Practice;2021-11-27